gastroesophageal cancer
BeiGene Nabs FDA Approval for Tevimbra With Chemo in First-Line PD-L1-Positive Gastric Cancer
Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.
Carsgen to Seek Approval in China for Satri-Cel in Claudin18.2-Expressing Gastric Cancer
The firm said the Phase III trial met its primary endpoint of improvement in progression-free survival.
European Commission Approves BeiGene's Tevimbra, Chemo in First-Line Gastric, Esophageal Cancers
The EC considered the treatment's activity in patients with advanced, PD-L1-positive esophageal and gastric cancers in the RATIONALE-305 and -306 trials.
CHMP Recommends BeiGene's Tevimbra for First-Line PD-L1-Positive Gastric, Esophageal Cancers
The recommendation was based on results from two Phase III trials showing that Tevimbra plus chemo improved overall survival over chemo alone.
FDA Approves Astellas' Vyloy, Chemo in First-Line CLDN18.2-Positive Gastric Cancer With Roche CDx
Vyloy is the first CLDN18.2-targeted treatment to reach the US market alongside Roche's Ventana CLDN18 RxDx Assay for identifying eligible patients.
Aug 27, 2024